Real world use of biologic drug levels and anti-drug antibodies in patients with psoriasis – does therapeutic drug monitoring have a place in routine clinical practice?

2021 ◽  
pp. 1-23
Author(s):  
Niamh Kearney ◽  
Kevin McKenna
Keyword(s):  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Real World ◽  
Drug Monitoring ◽  
Routine Clinical Practice ◽  
Therapeutic Drug ◽  
Drug Levels ◽  
Biologic Drug

Usefulness of Therapeutic Drug Monitoring of Antiretrovirals in Routine Clinical Practice

2004 ◽  
Vol 5 (4) ◽  
pp. 216-223 ◽  
Author(s):  
Michel Duong ◽  
Anne Golzi ◽  
Gilles Peytavin ◽  
Lionel Piroth ◽  
Marie Froidure ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Routine Clinical Practice ◽  
Therapeutic Drug

scholarly journals Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials

2018 ◽  
Vol 62 (7) ◽  
Author(s):  
David Andes ◽  
Laura Kovanda ◽  
A. Desai ◽  
Therese Kitt ◽  
M. Zhao ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Real World ◽  
Drug Monitoring ◽  
Antifungal Agents ◽  
Plasma Concentrations ◽  
Therapeutic Drug ◽  
Clinical Use

ABSTRACT Clinical use of voriconazole, posaconazole, and itraconazole revealed the need for therapeutic drug monitoring (TDM) of plasma concentrations of these antifungal agents. This need for TDM was not evident from clinical trials. In order to establish whether this requirement also applies to isavuconazole, we examined the plasma concentrations of 283 samples from patients receiving isavuconazole in clinical practice and compared the values with those from clinical trials. The concentration distributions from real-world use and clinical trials were nearly identical (>1 μg/ml in 90% of patients). These findings suggest that routine TDM may not be necessary for isavuconazole in most instances.

scholarly journals Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients

2021 ◽  
Vol 14 ◽  
pp. 175628482199990
Author(s):  
Sonia Facchin ◽  
Andrea Buda ◽  
Romilda Cardin ◽  
Nada Agbariah ◽  
Fabiana Zingone ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Point Of Care ◽  
Drug Clearance ◽  
Elisa Test ◽  
Enzyme Linked Immunosorbent Assay ◽  
Therapeutic Drug ◽  
Drug Concentrations ◽  
Inflammatory Bowel

Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are undetectable or sub-therapeutic. However, traditional immunoassay is not easily and rapidly accessible, making the translation of the results into treatment adjustment difficult. The availability of a point-of-care (POC) test for therapeutic drug monitoring (TDM) might represent an important step forward for improving the management of inflammatory bowel disease (IBD) patients in clinical practice. In this pilot study, we compared the results obtained with POC tests with those obtained by enzyme-linked immunosorbent assay (ELISA) in a group of IBD patients treated with Infliximab (IFX). We showed that POC test can reliably detect presence of antibody-to-IFX with 100% of specificity and 76% sensitivity, in strong agreement with the ELISA test ( k-coefficient = 0.84).

Sign in / Sign up

Export Citation Format

Share Document